(<i>Virginia Commonwealth University</i>) A new study led by scientists at VCU Massey Cancer Center suggests that gain-of-function mutations turn p53 into an oncogene, causing cells to replicate uncontrollably and contribute to cancer development. Recently published in Nature Communications, the researchers determined that mutant p53 genes are empowered by a specific protein, PLK3, to copy their genetic code and promote tumor cell proliferation through a process called transactivation.
(<i>Baylor College of Medicine</i>) Researchers have discovered that POT1, a gene known to be associated with risk of glioma, the most common type of malignant brain tumor, mediates its effects in a sex-specific manner.
(<i>University of Minnesota Medical School</i>) University of Minnesota Medical School researchers revealed why some glioblastoma patients see exceptional benefits from chemotherapy and survive beyond expectations.
(<i>New York University</i>) A team of researchers led by Assistant Professor of Mechanical and Biomedical Engineering and Principal Investigator at the NYU Abu Dhabi Mohammad A. Qasaimeh, have developed a new microfluidic system, called the Herringbone Microfluidic Probe (HB-MFP), that effectively isolates both CTCs and clusters of CTCs from blood samples of cancer patients for easier and more insightful analysis.
(<i>Istituto Italiano di Tecnologia - IIT</i>) MicroMESH is a new nanomedicine device capable to conform around the surface of tumor masses and efficiently deliver drugs. It is made of micrometric thick polymeric fibers which are very flexible and are arranged to form regular openings, which are also micrometric, just like the size of cancer cells. The new biomedical implant has been validated in preclinical studies that demonstrate its effectiveness for the treatment of glioblastoma multiforme. Published in Nature Nanotechnology.
(<i>University of California - San Francisco</i>) Researchers and physicians from the Occupational Safety and Health Administration (OSHA) and UC San Francisco have found that deaths of workers using methylene chloride paint strippers are on the rise. The solvent is widely used in paint strippers, cleaners, adhesives and sealants.
(<i>Stand Up To Cancer</i>) Stand Up To Cancer¬ģ (SU2C) and Mirati Therapeutics Inc. (NASDAQ: MRTX) - a late-stage targeted oncology company - announce that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst¬ģ program.
(<i>Albert Einstein College of Medicine</i>) Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was tested in rats, and the findings were published online today in JCI Insight.
(<i>University of Oklahoma</i>) A team of researchers at the OU College of Medicine has published a new study in the journal Gastroenterology, the world's leading publication on GI tract disease, that sheds new light on the ability of pancreatic cancer cells to spread throughout the body. Understanding why metastasis occurs is crucial for developing a therapeutic strategy to stop the spread.
(<i>University of Colorado Anschutz Medical Campus</i>) Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, Ph.D., co-leader of the Developmental Therapeutics Program, and Tin Tin Su, Ph.D., co-leader of the Molecular and Cellular Oncology Program.
(<i>Dartmouth College</i>) An initiative launched by Norris Cotton Cancer Center and the Magnuson Center for Entrepreneurship to bring new cancer treatments to patients more quickly makes its inaugural award announcment.
(<i>Tokyo Medical and Dental University</i>) Researchers at Tokyo Medical and Dental University (TMDU) have developed an ingenious therapeutic strategy against chronic myelomonocytic leukemia that links a cytotoxic drug payload to an antibody vector that targets the CD64 marker highly expressed by monocytes and monocytic progenitors. This selective antibody-drug conjugate spares other blood cell lineages thus avoiding the side-effects of conventional anti-cancer drugs such as anemia, infection or bleeding diatheses. Consequently, this drug-delivery tactic shows great promise against other monocyte-related diseases.
(<i>Centro Nacional de Investigaciones Oncol√≥gicas (CNIO)</i>) The researchers have discovered that USP7 inhibitors -under development by several pharmaceutical companies for the treatment of cancer- trigger a premature activation of cell cycle proteins, leading to uncontrolled cancer cell division and death.* The paper rejects the premise that the therapeutic efficacy of these inhibitors is due to their effects on activating the tumor suppressor protein P53, as currently accepted by the international scientific community. These results extend the potential use of USP7 inhibitors to a wider range of patients.
(<i>Oblique Therapeutics</i>) Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results in the highly-acclaimed scientific journal Science Advances (AAAS) entitled: Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular probes.
(<i>City of Hope</i>) With nearly half a century of outstanding contributions to the field of oncology nursing, City of Hope's Betty Ferrell, PhD, MA, CHPN, FAAN, FPCN, was selected by the ONS Board of Directors to receive the society's 2021 Lifetime Achievement Award. Ferrell is the director of the division of nursing research and education at City of Hope, principal investigator of the End-of-Life Nursing Education Consortium (ELNEC) project, and a world-renowned author and lecturer.
(<i>Cactus Communications</i>) Scientists have been exploring the cellular mechanisms underlying cancers for centuries in an attempt to successfully treat them. Collating recent research on one avenue of this exploration, the role of cell membrane receptor neuropilin-1, a review article published in Chinese Medical Journal gives a glimpse of how much we know of the disease, how much we still need to find out, and new promising treatments that we've begun to apply.
(<i>Cedars-Sinai Medical Center</i>) Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body's immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the US.
(<i>Northwestern University</i>) Novel insights into repair of DNA double-strand breaks (DSB), the most severe form of DNA damage, help scientists understand how proteins work to seal nicks.High resolution images show near-complete cycle of DSB detection and repair. Findings have implications in enhancing cellular response to radiation and chemotherapy.
(<i>Vanderbilt University Medical Center</i>) Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.
(<i>City University of Hong Kong</i>) Triple-negative breast cancer is an aggressive type of breast cancer with a high fatality rate. Currently, chemotherapy is the major treatment option, but the clinical result is unsatisfactory. A research team led by biologists at City University of Hong Kong (CityU) has identified and characterised a set of specific super-enhancers that stimulate the activity of the related critical cancer genes. The latest findings may help discover new effective drug targets for TNBC patients to improve their survival chance.
(<i>National Comprehensive Cancer Network</i>) National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
(<i>McMaster University</i>) McMaster University researchers Ali Ashkar and Sophie Poznanski have uncovered that changing the metabolism of natural killer (NK) immune cells allows these cells to overcome the hostile conditions found inside tumours and destroy advanced ovarian and lung cancer.
(<i>Link√∂ping University</i>) Despite surgery and subsequent treatment with chemotherapy and radiation, the majority of patients experience recurrence of malignant brain tumours. Researchers at Link√∂ping University, Sweden, and the Medical University of Graz, Austria, have shown in cells in culture that an ion pump can deliver drugs more accurately, which gives less severe adverse effects in chemotherapy. The results have been published in Advanced Materials Technologies.